Interleukin-2 for Refractory Chronic Spontaneous Urticaria
NCT ID: NCT06924762
Last Updated: 2025-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
124 participants
INTERVENTIONAL
2025-03-19
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does IL-2 alleviate the symptoms of urticaria in patients? What medical problems do participants have when given IL-2? Researchers will compare IL-2 to a placebo (a look-alike and smell-like substance that contains no IL-2) to see if IL-2 works to treat refractory, moderate to severe CSU.
Participants will:
Receive IL-2 or a placebo intramuscular injections for 3 rounds at Week 0, 4 and 8, in which each round includes one injection daily for seven consecutive days.
Visit the clinic for checkups and tests at Week 2, 4, 8, 12 and 24. Keep a diary of their symptoms and the number of tablets of oral antihistamines.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria
NCT04893980
Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria
NCT04944602
Trial of JYB1904 in Chronic Spontaneous Urticaria.
NCT06509334
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
NCT07166211
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
NCT01292473
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Urticaria is a common disorder characterized by localized edema due to dilation and increased permeability of small blood vessels in the skin and mucous membranes. The primary clinical manifestations include wheals and pruritus.
Chronic spontaneous urticaria (CSU) is defined as recurrent, transient (\<24 hours), pruritic wheals on the skin and mucosa lasting for more than 6 weeks, with or without angioedema, excluding chronic inducible urticaria. Among patients with chronic urticaria, about 2/3 have CSU. Although the pathogenesis of CSU remains unclear, increasing evidence suggests an autoimmune feature of this disorder. Oral antihistamines are the primary treatment for CSU, yet some patients continue to experience symptoms despite treatment with standard or double doses. Recent studies have shown that human IL-2 (Interleukin-2) can be effective in a proportion of CSU patients refractory to antihistamine treatment, without significant side effects. Therefore, in this clinical trial we aim to evaluate the therapeutic effect and safety of this new therapeutic method.
Study Design:
This is a randomized, placebo-controlled, multi-center clinical trial to evaluate the safety and efficacy of IL-2 treatment in CSU patients who remain symptomatic despite oral antihistamine treatment.
Methods:
CSU patients who meet the inclusion criteria will receive IL-2 or placebo intramuscular injections in combination with their current antihistamine regimen (either a single antihistamine or a combination of two to three antihistamines at a dose of at least the standard dosage). Endpoints include clinical response, quality of life, and safety profiles.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interleukin-2 treatment group
The enrolled subjects will receive three cycles of interleukin-2 treatment in the first 12 weeks upon initiation of the intervention, while continuing with the same oral regimen of second-generation antihistamines as they have been receiving before initiation of the trial. In each cycle of interleukin-2 treatment, the enrolled subjects will receive an intramuscular injection of interleukin-2 at a dosage of 1 million international units, dissolved in 1.0 mL of sterile water for injection, once daily for 7 consecutive days. The three cycles of interleukin-2 treatment will be administered on Day 0\~6, Day 28\~34 and Day 56\~62, respectively.
Human interleukin-2 (I) intramuscular injection
On the basis of background treatment, intramuscular injection of human interleukin-2 (I) will be added.
Placebo group
The enrolled subjects will receive three cycles of placebo injections in the first 12 weeks upon initiation of the intervention, while continuing with the same oral regimen of second-generation antihistamines as they have been receiving before initiation of the trial. In each cycle of placebo injections, the enrolled subjects will receive an intramuscular injection of placebo at a same specification as in the IL-2 treatment group, dissolved in 1.0 mL of sterile water for injection, once daily for 7 consecutive days. The three cycles of placebo injections will be administered on Day 0\~6, Day 28\~34 and Day 56\~62, respectively.
Placebo intramuscular injection
On the basis of background treatment, intramuscular injection of placebo was added.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo intramuscular injection
On the basis of background treatment, intramuscular injection of placebo was added.
Human interleukin-2 (I) intramuscular injection
On the basis of background treatment, intramuscular injection of human interleukin-2 (I) will be added.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosed with chronic spontaneous urticaria (CSU) (including patients overlapped with chronic inducible urticaria) according to the 2021 EAACI/GA²LEN/EDF/AAAAI guidelines;
3. Disease course of CSU for at least 12 weeks;
4. The patient has been treated with second-generation antihistamines (one or more types, up to 4 tablets per day) every day for 2 weeks or more but still experiences significant symptoms of wheals and/or itching, with a UAS7 score ≥16 or a UCT score \<12;
5. UAS7 ≥16 on the date prior to randomization (according to complete daily symptom log data recorded in the past 7 days before randomization);
6. Willing and able to complete daily symptom logs throughout the entire study period;
7. The patient voluntarily consents to participate in this research project and has signed the informed consent.
Exclusion Criteria
* Has used corticosteroids, immunosuppressants, leukotriene receptor antagonists, H2 receptor antagonists, intravenous immunoglobulin (IVIG) therapy, and/or undergone plasma exchange in the past 4 weeks;
* Has received omalizumab or other biologic treatments in the past 12 weeks;
* Has previously undergone interleukin-2 treatment;
* Has a history of anaphylactic shock;
* Plans or anticipates the use of any prohibited drugs or treatments during the screening and/or treatment periods;
* Currently has active or recurrent severe infections, such as active tuberculosis;
* Has a congenital or acquired immunodeficiency disorder;
* Has a history of drug or alcohol abuse, mental disorders, or poor compliance, making them unable to adhere to treatment;
* Currently enrolled in another clinical trial;
* Is an employee of the clinical research facility or directly involved in the study, or is an immediate family member of such an individual;
* Any other reason that makes participation in this trial inappropriate.
18 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiangya Hospital of Central South University
OTHER
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Tongji Hospital
OTHER
West China Hospital
OTHER
First Affiliated Hospital of Guangxi Medical University
OTHER
Fujian Medical University Union Hospital
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER
The First People's Hospital of Changde City
OTHER
The Third People's Hospital of Hangzhou
OTHER
Second Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hai Long
M.D., Ph.D. & Vice President, The Second Xiangya Hospital of Central South University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hai Long, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Second Xiangya Hospital of Central South University
Qianjin Lu, MD, PhD
Role: STUDY_DIRECTOR
Second Xiangya Hospital of Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MR-43-25-003708
Identifier Type: OTHER
Identifier Source: secondary_id
LYG20240044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.